Research & Development

Can FOLFIRINOX Be a Second-Line Standard in Biliary Cancer?
Research & Development Can FOLFIRINOX Be a Second-Line Standard in Biliary Cancer?

After first-line therapy fails in advanced biliary cancer, the next decision can stretch between hope for extra months and fear of heavy toxicity, a fraught balance that now places FOLFIRINOX squarely under the spotlight. Clinics see this crossroads every week: a patient who just progressed on

Can Music and Recovery Care Speed CRC Surgery Recovery?
Research & Development Can Music and Recovery Care Speed CRC Surgery Recovery?

In operating rooms where silence often amplifies stress, a small change—a pair of headphones and a vigilant recovery plan—can shift the arc of the first hours after colorectal cancer surgery, easing the path from anesthesia to wakefulness while trimming complications that make families and

Moderate Coffee Tied to Longer Telomeres in Mental Disorders
Research & Development Moderate Coffee Tied to Longer Telomeres in Mental Disorders

A daily habit as ordinary as pouring a third or fourth cup of coffee may have aligned with a five-year edge in biological aging among people living with schizophrenia and mood disorders, hinting that moderation could matter more than any exotic supplement. The notion is surprising because coffee

Treg Priming vs. Broad Immunosuppression: A Comparative Analysis
Research & Development Treg Priming vs. Broad Immunosuppression: A Comparative Analysis

When a lifesaving transplant risks unleashing the very immune fire meant to cure leukemia, choices about how to steer immunity before donor cells arrive determine whether patients heal or face harm. That dilemma sits at the heart of allogeneic hematopoietic stem cell transplantation, where

Can Romidepsin Revive Chemo in Relapsed Neuroblastoma?
Research & Development Can Romidepsin Revive Chemo in Relapsed Neuroblastoma?

Jan Kaiserle sits down with Ivan Kairatov, a biopharma expert deeply versed in molecular therapeutics and translational research, to discuss a new approach to overcoming treatment resistance in neuroblastoma. Drawing on work published in Science Advances in 2025, Kairatov explains how a failed

Fungi in Cancer: From Tumor Ecology to Targeted Therapies
Research & Development Fungi in Cancer: From Tumor Ecology to Targeted Therapies

If bacteria aren’t the whole story of the tumor microenvironment, what crucial signals are being missed from fungi that quietly occupy the same space yet account for only a sliver of the sequencing reads but a disproportionate share of immune cues and clinical outcomes? That challenge has gained

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later